Bicycle Therapeutics plc (50BA) - Net Assets
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has net assets worth €609.98 Million EUR (≈ $713.13 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€717.60 Million ≈ $838.95 Million USD) and total liabilities (€107.62 Million ≈ $125.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 50BA current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €609.98 Million |
| % of Total Assets | 85.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | 76.16% |
| 10-Year Change | N/A |
| Growth Volatility | 101.17 |
Bicycle Therapeutics plc - Net Assets Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's net assets have evolved over time, based on quarterly financial data. Also explore Bicycle Therapeutics plc total assets for the complete picture of this company's asset base.
Annual Net Assets for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual net assets of Bicycle Therapeutics plc from 2018 to 2025. For live valuation and market cap data, see 50BA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
-23.09% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
+113.80% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
+36.98% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
-21.80% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
+262.72% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
+2.43% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
+233.47% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bicycle Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 82980900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.51 Billion | 247.51% |
| Total Equity | €609.98 Million | 100.00% |
Bicycle Therapeutics plc Competitors by Market Cap
The table below lists competitors of Bicycle Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
$230.47 Million |
|
Starz Entertainment LLC
NASDAQ:STRZ
|
$230.69 Million |
|
Panca Budi Idaman Tbk PT
JK:PBID
|
$230.72 Million |
|
Jiangsu Zhongshe Group Co Ltd
SHE:002883
|
$230.79 Million |
|
Alvopetro Energy
V:ALV
|
$230.37 Million |
|
908 Devices Inc
NASDAQ:MASS
|
$230.37 Million |
|
Salmon Evolution Holding AS
OL:SALME
|
$230.25 Million |
|
Sonmez Filament Sentetik Iplik ve Elyaf Sanayi AS
IS:SONME
|
$230.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bicycle Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 793,060,000 to 609,977,000, a change of -183,083,000 (-23.1%).
- Net loss of 218,960,000 reduced equity.
- Other factors increased equity by 35,877,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-218.96 Million | -35.9% |
| Other Changes | €35.88 Million | +5.88% |
| Total Change | €- | -23.09% |
Book Value vs Market Value Analysis
This analysis compares Bicycle Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-3.95 | €3.92 | x |
| 2019-12-31 | €5.18 | €3.92 | x |
| 2020-12-31 | €4.53 | €3.92 | x |
| 2021-12-31 | €11.71 | €3.92 | x |
| 2022-12-31 | €9.06 | €3.92 | x |
| 2023-12-31 | €8.74 | €3.92 | x |
| 2024-12-31 | €11.48 | €3.92 | x |
| 2025-12-31 | €8.79 | €3.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bicycle Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -301.66%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.18x
- Recent ROE (-35.90%) is below the historical average (-31.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -306.14% | 0.09x | 0.00x | €-14.86 Million |
| 2019 | -32.84% | -221.78% | 0.13x | 1.18x | €-39.93 Million |
| 2020 | -53.44% | -490.95% | 0.06x | 1.69x | €-60.56 Million |
| 2021 | -19.30% | -571.25% | 0.02x | 1.39x | €-101.44 Million |
| 2022 | -41.63% | -779.35% | 0.04x | 1.52x | €-139.80 Million |
| 2023 | -48.71% | -669.72% | 0.05x | 1.60x | €-217.76 Million |
| 2024 | -21.31% | -479.18% | 0.04x | 1.21x | €-248.34 Million |
| 2025 | -35.90% | -301.66% | 0.10x | 1.18x | €-279.96 Million |
Industry Comparison
This section compares Bicycle Therapeutics plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $555,085,471
- Average return on equity (ROE) among peers: -68.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bicycle Therapeutics plc (50BA) | €609.98 Million | 0.00% | 0.18x | $230.38 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $-48.21 Million | 0.00% | 0.00x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.83 Billion | 9.08% | 0.22x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more